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Objectives: This retrospective study was aimed to explore the epidemiological and clinical
proﬁles of Mycoplasma pneumoniae infection in neonates.
Methods: From 2011 to 2014, 1322 hospitalized neonates with lower respiratory tract infec-
tions were screened for Mycoplasma pneumoniae by detection of Mycoplasma pneumoniae
antibodies using Serion ELISA classic Mycoplasma pneumoniae kits.
Results: Mycoplasma pneumoniae was identiﬁed in 89 (6.7%) patients. The age ranged from 1
day to 28 days with a median of 22 days. The male to female ratio was 1.15:1. Mycoplasma
pneumoniae infection peaked in spring (from March through May) and winter (from December
through February). Compared with non-Mycoplasma pneumoniae infected neonates, those
with Mycoplasma pneumoniae infection were older, presented fever more frequently, and had
less  tachypnea.
Conclusions: Mycoplasma pneumoniae could be an important etiologic agent for respiratory
tract  infection in neonates. In neonates Mycoplasma pneumoniae infection was usually asso-ciated with older age, presence of fever, and less tachypnea. Mycoplasma pneumoniae infection
in  neonates tends to be a mild process.
ier Ed
ies have been conducted to elucidate the role of MP  in neonatal©  2016 Elsev
Introduction
Mycoplasma pneumoniae (MP) is an important cause of
community-acquired pneumonia in children.1,2 MP causes
respiratory tract infection in all age groups.3 Nonetheless, the
main burden of infection is typically found in school-age chil-
dren. An increasing incidence of MP  infection and disease
in children and infants under ﬁve years is being reported.4–7
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However, the relevance of MP  as an etiological agent of
neonatal lower respiratory tract infections (LRTIs) remains
unclear.
To the best of our knowledge, MP as an etiological agent of
neonatal LRTIs has occasionally been reported,8,9 but no stud-LRTIs in China and other regions throughout the world. Thus
it is important to delineate the extent of involvement of MP  in
neonatal LRTIs.
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The monthly distribution of MP infection in neonates is
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Toward that end, we  investigated the occurrence of MP
nfection in 109 hospitalized neonates with LRTIs from 2011
o 2014 and further analyzed the incidence, clinical, and labo-
atory data of these cases.
aterials  and  methods
atients
 total of 1322 neonates hospitalized with LRTIs in Children’s
ospital of Soochow University, China, from Jan 2011 to Dec
014 were selected for this observational retrospective study.
o be included in this study, patients had to be aged less 29
ays and be hospitalized for LRTIs during the study period.
RTI was deﬁned as the presence of at least three of the follow-
ng signs and symptoms: cough, tachypnea, chest retractions,
bnormal auscultatory ﬁndings (wheezing or crackles), and
adiologic evidence indicative of lower respiratory tract infec-
ion. The exclusion criteria were: neonates with a vertical
nfection (i.e., an infection transmitted from mother to child)
r infection acquired during delivery. The study was approved
y the Ethics Committee of Children’s Hospital of Soochow
niversity.
ata  collection
atient demographic data, laboratory and radiographic reports
ere collected and reviewed. Laboratory data including
eripheral white blood cell count, neutrophil and lympho-
yte proportions, C-reactive protein (CRP), serology for MP, and
asopharyngeal specimens for viral testing were recorded and
urther analyzed.
erology  for  MP
peciﬁc IgM and IgG antibodies against MP  were detected
n serum samples of patients in the acute phase of MP
on admission) and convalescent phase (on discharge), using
 commercial ELISA kit (Serion ELISA classic MP IgG/IgM,
nstitute Virion/Serion, Würzburg, Germany) according to
he manufacturer’s instructions. The presence of IgM in
he convalescent phase was used as criteria of current MP
nfection.
asopharyngeal  specimen  collection
asopharyngeal secretions were collected from each study
articipant within 24 h after admission by a lab technician
s previously described. Brieﬂy, an aseptic plastic spu-
um catheter was inserted into the nostril to a depth of
bout 7–8 cm until reaching the pharynx. Approximately
 mL  of nasopharyngeal secretions was collected by apply-
ng negative pressure. The sample was mixed with 4–8 mL
BS, and centrifuged for 10 min  at 300–500 rpm. The super-
atant was discarded and the pellet was mixed with 4–8 mL
BS and centrifuged for an additional 10 min. The spec-
mens were centrifuged and were stored at −80◦ C until
ested.6;2 0(4):374–378 375
Detection  of  viruses
All nasopharyngeal swabs were tested by immunoﬂuores-
cence for antigen detection of seven common viruses,
including respiratory syncytial virus (RSV), adenovirus (ADV),
inﬂuenza viruses (IV) A and B, and parainﬂuenza viruses (PIV)
1, 2 and 3.
Statistical  analysis
We  used n (%) for categorical variables and median (range) for
continuous variables with non-normal distribution or mean
(SD) for those with normal distribution. We assessed differ-
ences in categorical variables with the 2 test. We calculated
95% CI for differences in medians with an exact test. SPSS
(version 17.0) software was used for all statistical analysis.
Multivariate logistic regression analysis was used to analyze
variables associated with detection of MP.
Results
Patient  demographics
A total of 1322 neonates hospitalized with LRTIs were included
in this study. Of those, MP  was identiﬁed in 89 (6.7%) patients,
with RSV in 255 (19.3%) cases, 59 (4.7%) with IV-A, 13 (1.0%) with
PIV-3, 9 (0.7%) with IV-B, and 8 (0.6%) with ADV. Multi-viruses
were identiﬁed in 36 (2.7%) patients. Among the 89 patients
with MP infection, 16 patients (17.8%) were co-infected with
RSV, and one (1.1%) was co-infected with inﬂuenza A.
Age ranged from 1 day to 28 days with a median of 22 days.
The male to female ratio was 1.15:1. The birth weight ranged
from 2150 to 4000 g with a median of 3450 g. Gestational age
ranged from 33 to 41 weeks with a median of 37 weeks.
Epidemiology  of  MP  infection
The age distribution of MP infection in neonates is shown
in Fig. 1. Three (3.4%) cases were aged 1–7 days, 11 (12.4%)
8–14 days, 28 (31.5%) 15–21 days, and 47 (52.8%) were aged




Fig. 1 – The age distribution of Mycoplasma pneumoniae
infection in neonates.























Fig. 2 – The seasonal distribution of Mycoplasma
pneumoniae infection in neonates.
through May)  and winter (from December through February),
which involved 30 cases (33.7%) in spring, and 28 (31.5%) cases
in winter, respectively, compared with 16 cases (18.0%) in
summer (June to August), and 15 (16.9%) in autumn (from
September to November). The prevalence of MP infection was
higher during winter and spring, and lower in summer and
autumn.
Clinical  features,  laboratory  and  radiographic  ﬁndings
The main clinical features of the patients with MP infection
are shown in Table 1. Eighty-one (91.0%) patients had cough.
Dyspnea or tachypnea was observed in 47 (52.8%) patients,
wheezing in 9 (10.1%), and fever (temperature, >38 ◦C) in 43
(48.3%) patients. Mean WBC  counts were 11.2 ± 3.2 × 109 L–1;
CRP were >10 mg/mL  in eight (9.0%) patients. Liver enzyme,
Table 1 – Demographic and general characteristics of
neonates with Mycoplasma pneumoniae (MP) infection.
Demographic and general characteristics MP infection
(n = 89)
Males/females 1.15:1
Age, days, median (range) 22 (1–28)
Pregnancy and delivery characteristics
Gestational age, weeks, median (range) 37 (33–41)
Preterm delivery (<37 wk), n (%) 4 (4.5)
Cesarean section, n (%) 31 (34.8)
Respiratory symptoms and signs [n, (%)]





WBC, ×109 L–1, median (range) 11.2 ± 3.9
CRP > 10 mg/dL, n (%) 8 (9.0)
ALT > 40 U/L, n (%) 7 (7.9)
Treatment
Antibiotics, n (%) 109 (100)
Oxygen supplementation, n (%) 3 (2.7)
Continuous positive airway pressure, n (%) 1 (0.9)
Mechanical ventilation, n (%) – 1 6;2  0(4):374–378
alanine aminotransferase level was above the upper limit of
normality in seven (7.9%) patients.
Chest radiographs of all patients were available for
review. Peribronchial inﬁltration and perihilar inﬁltration were
observed in 81 (91.0%) children. Homogenous consolidation
was  present in seven (7.9%) patients. None of the patients
presented with pleural effusion.
Variables  associated  with  MP  infection
Demographic and clinical characteristics from Table 1 were
compared between neonates with MP infection (n = 89) and
those with non-MP infection (n = 1233). From this univariate
analysis, three predictor variables, namelyage, fever (tem-
perature ≥ 38◦ C) and tachypnea were evaluated in a logistic
regression model: compared to non-MP cases MP  cases were
older (median of 22 days vs 14 days), had more  fever (48.3%
vs 13.5%), and less tachypnea (52.8% vs 63.2%) (see Table 2 for
statistics).
Prognosis
Overall, three (3.4%) out of 89 patients with MP  infection
required supplemental oxygen. None required mechanical
ventilation. The median length of hospital stay was seven
(4–12) days. Duration of follow-up was one month for 83 chil-
dren. None of the patients had residual pulmonary disease.
Comparison  of  clinical  characteristics  of  patients  with  MP,
RSV, and  multi-virus  infection
The clinical characteristics of MP, RSV, and multi-viruses infec-
tion are shown in Table 3. The median age was 22 days for
MP patients, 17 days for RSV patients, and 18 days for multi-
viruses patients. Fever was more  common in children with
MP than either RSV or multi-viruses infection (both p < 0.01).
Tachypnea and oxygen supplementation were more  often
present in children with RSV than with MP  infection (both
p < 0.01). The median length of hospital stay was longer in chil-
dren with RSV and multi-viruses infection than for those with
MP infection (both p < 0.01).
Discussion
Respiratory infections are the most common cause of neonatal
morbidity and mortality, despite many  advances in neonatal
intensive care. MP is often the etiological agent of respi-
ratory infections in children older than ﬁve years and in
adolescents.10 In recent years, the role of MP  in children and
infants under ﬁve years has been reported.5–7,11 However, no
large sample studies have focused on neonatal MP infection.
This retrospective study describes the epidemiology and clin-
ical features of MP in neonates during four consecutive years.
In that period, 8.2% of the neonates were found to be infected
with MP.  Previous studies12 have found that 21.6% of two-year
old patients had positive throat swabs for MP.  Wang et al. also
found that bronchiolitis due to MP  was mainly seen in infants
aged 6 months to one year with a detection rate of 23.9%. In
our study, the incidence of MP infection was lower than that
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Table 2 – Risk of Mycoplasma pneumoniae (MP) infection per selected variable.
Variable MP infection (n = 89) Non-MP infection (n = 1233) Unadjusted OR (95% CI) Adjusted OR (95% CI)a
Age, days 22 (1–28) 14 (1–28) 1.11 (1.07–1.14) 1.11 (1.07–1.14)
Sex, males 48 (53.9) 698 (56.6) 0.71 (0.44–1.16) –
Preterm delivery 4 (4.5) 101 (8.2) 0.50 (0.19–1.27) –
Fever (temperature, ≥38 ◦C) 43 (48.3) 167 (13.5) 4.48 (2.65–7.57) 6.23 (3.01–9.34)
Tachypnea 47 (52.8) 779 (63.2) 0.47 (0.30–0.74) 0.1 (0.04–0.21)
Wheeze 9 (10.1) 874 (7.2) 1.01 (0.71–1.21) –
Data are presented as median (range) or n (%).
CI, conﬁdence interval; OR, odds ratio.
a Adjusted for age and sex.
Table 3 – Comparison of clinical characteristics of patients with MP, RSV and multi-virus infection.
Demographic and general characteristics MP (n = 89) RSV (n = 255) Multi-virus (n = 36)
Males, n (%) 48 (53.9) 139 (54.5) 21 (58.3)
Age, days, median (range) 22 (1–28) 17 (12–22) 18 (9–20)
Pregnancy and delivery characteristics
Gestational age, weeks, median (range) 37 (33–41) 37 (31–41) 37 (34–41)
Preterm delivery (<37 wk), n (%) 4 (4.5) 17 (6.7) 3 (8.3)
Cesarean section, n (%) 31 (34.8) 79 (31.0) 12 (33.3)
Breast feeding 71 (79.7) 201 (78.8) 28 (77.8)
Respiratory symptoms and signs [n, (%)]
Fever (temperature, ≥38 ◦C) 43 (48.3)a 58 (22.7) 10 (27.8)
Cough 81 (91.0) 241 (94.5) 36 (100)
Tachypnea 47 (52.8)b 158 (62.0) 21 (58.0)
Wheeze 9 (10.1.) 23 (9.0) 3 (8.3)
Laboratory results
WBC, ×109 L–1, median (range) 11.2 ± 3.2 10.5 ± 3.6 10.9 ± 3.4
CRP > 10 mg/dL, n (%) 8 (9.0) 21 (8.0) 4 (11.1)
ALT > 40 U/L, n (%) 7 (7.9) 25 (9.8) 2 (5.6)
Oxygen supplementation, n (%) 3 (2.7)a 39 (15.3) 4 (11.1)
Mechanical ventilation, n (%) 0 10 (3.9) 1 (2.8)
Hospital stay, days, median (range) 7 (4–12)a 10 (9–14) 9 (7–14)


















ia p < 0.01 compared with RSV and multi-virus infection.
b p < 0.01 compared with RSV infection.
hown in previous studies and concentrated in children less
han two years.
During the early phase of MP  infection, PCR can be a useful
iagnosis tool in young or immunocompromised patients who
ay not be able to mount an adequate immune response to
P.13–15 However, a recent study indicated that the presence
f MP  in the upper respiratory tract is common in asymp-
omatic children.16 Realtime PCR therefore does not represent
n unambiguous method for the diagnosis of symptomatic
.  pneumoniae infections.16,17 Accordingly, in our study we
sed MP-IgM, instead of PCR, to diagnose MP  infection. IgM
s usually produced one to two weeks after the initial MP
nfection.2 The presence of IgM in the convalescent phase
as a criterium for current MP  infection. Therefore, we
elieve that our deﬁnition for MP  infection was better sur-
ogate marker for an existent MP  infection in neonates with
RTI.MP infections can occur endemically throughout the year
r in epidemics. Epidemics of MP  infection were common dur-
ng the winter and spring in this study. However, previousstudies showed that MP infection in children peaks in
May through July (summer) and in August through October
(autumn).11,18 Thus, the outbreaks of MP infection may differ
in countries with different climates.
The clinical presentation of MP infection was compared
with that of non-MP infection. MP infection was associated
with older age and fever was more  common compared with
non-MP infection. However, tachypnea was less common in
MP infection. Our ﬁndings are in line with our previous study
which described the clinical proﬁle of MP  infection in chil-
dren with bronchiolitis.4 Wang et al.4 found that patients with
MP bronchiolitis were older and fever was more  common, but
tachypnea was less common in patients with MP  bronchiolitis
compared with RSV bronchiolitis. However, in the study by He
et al.,3 tachypnea and fever were not signiﬁcantly associated
with respiratory infection due to MP. This difference may prob-
ably be explained by the different age range of the enrolled
patients. The study reported by He et al. enrolled children of all
age groups. The clinical proﬁle of MP may differ with different
age groups.
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Non-resolving pneumonia caused by MP  was reported in a
neonate.9 However, in our study MP  infection was generally a
mild process in all neonates. MP  single infection cases neither
needed oxygen therapy nor required mechanical ventilation.
Our study has some limitations. First, our cases were iden-
tiﬁed retrospectively with data limited to that available in the
medical records. The use of retrospective data also made it dif-
ﬁcult to accurately assess the role of MP  infection in neonates
with LRTI. A second limitation was the absence of asymp-
tomatic control patients.
Conclusion
Our results suggest that MP  might be an important etiologic
agent for lower respiratory tract infection in neonates. MP
infection in neonates was usually associated with older age,
fever, and less tachypnea.
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